Medical Student Research Fellowship for Summer 2008
Mentor: Ugis Gruntmanis
Department: Medicine/Endocrinology
Room number: Y5, 322B
Mail Code: 8857
Phone number: 214-648-2215
E-mail: ugis.gruntmanis@utsouthwestern.edu
Project title:
1. A one year, placebo-controlled, double blind study to assess the effect
of oral ibandronate 150mg Q monthly versus placebo on LS bone mineral density
in men with osteoporosis.
2. Retrospective database analysis on efficacy of alendronate and zolodronic
acid in treatment of male osteoporosis.
3. Post US approval voluntary registry study to determine incidence of hypocalcemia
post zoledronic acid treatment in patients with Paget's disease.
Human subjects IRB approved project number (where applicable):
#0102-022
#07-056
#P
Animal subjects IRB approved project number (where applicable):
N/A
Project Type (patient-based research, animal-based research, or basic research; this characterization is only to permit a general classification for grouping similar types of projects). Both of the projects are patient oriented.
Brief Description of Project:
1. Ibandronate (Boniva) once monthly dose is approved treatment for women with osteoporosis. This study will look if Ibandronate increases bone mineral density in men.
2. Alendronate (Fosomax) is FDA approved treatment for male osteoporosis, zolodronic acid (Zometa) once a year is used in patients who can not tolerate oral treatment yet is not FDA approved treatment. We will compare changes in bone mineral density with alendronate and zolodronic acid.
3. Hypocalcemia has been described after infusion of zoledronic acid for osteoporosis
or Padget's disease yet frequency of this side-effect has not been systematically
studied.
This study will strive to answer this question.
Previous Research Activities or Publications with Medical Students:
1.Gruntmanis U, Leach B, Odvina CV, Zerwekh JE, Sakhaee K
High Rate of Hypogonadism and Vitamin D Insufficiency in Males on Dialysis.
J Bone Miner Res. 2005; 20 (suppl 1): M468
2. Kaloyanova P, Patel V, Ghayee H, Gruntmanis U. No Difference in Prevalence
of Pituitary Imaging Abnormalities in Secondary Hypogonadal Men Presenting with
Osteoporosis versus Erectile Dysfunction.
Presented at 88th Endocrine Society meeting in Boston 6/2006
3. Fontenot A and Gruntmanis U. Comparison of Alendronate and Zoledronic Acid Treatments in Men with Low Bone Mineral Density. Abstract presented at 46th UT Southwestern Annual Medical Student Research Forum 11/22/2008. Dallas, TX